

Index

- A β peptides, CSF, 145–6, 147
 acetylcholinesterase inhibitors, 37, 232–3, 245
 activities of daily living (ADLs), 211–13
 anatomical correlates, 221–2
 basic, 211, 212
 behavioral variant FTD, 213–14, 215, 216, 220
 cognitive and behavioral changes and, 214, 220–2
 corticobasal degeneration, 220, 221
 evaluation, 212
 instrumental, 211–12
 logopenic progressive aphasia, 219–20
 management strategies, 223–4
 progressive non-fluent aphasia, 217–18, 219, 220
 progressive supranuclear palsy, 220, 221
 semantic dementia, 216–17, 218, 219, 220
 Addenbrooke's Cognitive Examination (ACE), 99, 106–7
 Advanced Caregiver Training (ACT), 237
 affective disorders, differential diagnosis, 34–5
 age at presentation, 92
 aggression, 231–2, 236–7
 agitation, 231–2, 236–7
 agnosia
 associative, 4, 32
 multimodal, semantic dementia, 20
 agrammatism, 18, 32, 57
 Akelaitis variant frontotemporal dementia, 82
 alien hand syndrome, 20
 alkalinizing drugs, 251
 ALS. *See* amyotrophic lateral sclerosis
 Alzheimer, Alois, 2
 Alzheimer's disease (AD)
 clinicopathologic correlation, 23
 CSF biomarkers, 143, 146–7
 differential diagnosis, 23–4, 33–4
 frontal variant, 181
 imaging, 137
 tau protein, 84
 TDP-43 pathology, 176–7
 type pathology, logopenic progressive aphasia, 61–2
 Alzheimer's Disease Research Centers Program, 269
 Alzheimer's Prevention Initiative (API), 254
 amiodarone, 251
 amnesic aphasia, 1, 4
 amyloid- β biomarkers, CSF, 145–6, 147
 amyotrophic lateral sclerosis (ALS; motor neuron disease; MND)
 frontotemporal cognitive-behavioral syndromes, 70
 FTD with. *See* frontotemporal dementia-amyotrophic lateral sclerosis
 genetics, 190
 overlap with FTD, 8, 20–1, 68–9
 pathologic substrate, 7
 with behavioral impairment (ALSbi), 70
 with cognitive impairment (ALSci), 70
 Amyotrophic Lateral Sclerosis Cognitive Behavioral Screen (ALS-CBS), 74
 animal models, 197–206
 C9orf72 repeat expansion, 199
 CHMP2B mutations, 206
 drug development, 252–4
 FTLD-TDP, 177, 204–5
 FUS proteinopathy, 180, 204–5
 GRN mutations, 203, 253–4
 tauopathies (FTLD-tau), 171, 200, 201
 VCP mutations, 205
 anomia/naming deficits
 imaging correlates, 138
 management, 232
 primary progressive aphasia, 18
 semantic dementia, 4, 19, 59
 anterior cingulate atrophy, 125–6, 130
 Anti-Amyloid Treatment in Asymptomatic Alzheimer's disease (A4) studies, 254
 antidepressants, 37, 231, 244–5
 anti-epileptics, 247
 antipsychotics, 37, 231–2, 245–6
 antisense oligonucleotides (ASO), 252
 apathy/inertia
 behavioral variant FTD, 16, 31, 46
 case study, 38–9
 differential diagnosis, 96, 97
 FTD-ALS, 8, 73
 imaging studies, 138
 management, 215, 232, 235
 aphasia. *See also* language disturbances
 amnesic, 1, 4
 Gogi, 4
 management, 232
 progressive
 bvFTD, 17
 differential diagnosis, 24
 primary. *See* primary progressive aphasia
 transcortical sensory, 4, 19
 applause sign, 85
 apraxia
 corticobasal degeneration, 20
 management, 218
 neuroanatomical correlates, 59
 progressive non-fluent aphasia, 18, 57
 apraxia of speech (AOS), 18, 32, 57
 imaging studies, 138
 arginine hypomethylation, FET proteins, 178, 180
 argyrophilic grain disease (AGD), 169, 171
 aripiprazole, 246
 arterial spin labeling (ASL) perfusion imaging, 128
 Association for Frontotemporal Degeneration (AFTD), 230, 265, 267–8, 270
 associative agnosia, 4, 32
 astrocytes, tufted, 168
 astrocytic plaques, 170
 attention-deficit hyperactivity disorder (ADHD), 98
 attentional tests, 107
 atypical frontotemporal lobar degeneration with ubiquitin-positive pathology (atypical FTLD-U), 22, 177, 178, 179
 Auditory-Verbal Learning Test (AVLT), 108

- augmentative and alternative communication devices (AACs), 234–5
- autism spectrum disorders (ASD), 98
- autobiographical memory tests, 108–9
- autoimmune conditions, systemic, 251
- Awareness of Social Inference Test – Revised (TASIT-R), 113–14
- backward digit span test, 110
- basal ganglia disorders, degenerative, 95
- basophilic inclusion body disease (BIBD), 22, 177, 179, 180
- behavioral assessment. *See also* neuropsychological testing
 behavioral variant FTD, 47–8
 FTD-ALS, 73–4
- behavioral disturbances
 behavioral variant FTD, 16–17, 31, 45–7
 FTD-ALS, 73
 imaging studies, 137–8, 139
 impact on activities of daily living, 220–2
 management, 223–4, 231–2, 235–7
 primary progressive aphasia, 18
 semantic dementia, 20, 32
- behavioral variant frontotemporal dementia (bvFTD), 3, 44–51, 92, 93–4
 behavioral features, 16–17, 31, 45–7
 case studies, 38, 225–6
 classification, 5–6
 clinical presentation, 31–2
 clinical syndrome, 16–18
 clinicopathologic correlation, 17, 23
 cognitive features, 31–2, 48–9
 diagnosis, 45, 229
 differential diagnosis, 23–4, 96
 emotion, social cognition and decision-making, 50–1
 functional disability, 213–14, 215, 216, 220
 imaging, 125–6, 128, 130, 133
 imaging–behavior correlations, 137–8
 management, 234
 measuring behavioral changes, 47–8
 measuring cognition, 49
 neuropsychological testing, 106–16
 overlap with ALS/MND, 69
 pathology, 7, 44, 181
 phenocopies, 3, 25, 35, 94, 130
 primary progressive aphasia vs., 133
 prognosis, 102
- biomarkers, cerebrospinal fluid (CSF), 101, 143–6, 148, 255
- bipolar disorder, differential diagnosis, 96
- Boston Naming Test, 118
- bromocriptine, 246, 247
- C9orf72* repeat expansion, 69, 188–9, 197–9
 animal models, 199
 antisense oligonucleotides (ASO), 252
 case history, 157–8, 159
 clinical presentation, 187, 189
 dipeptide repeat (DPR) pathology, 175–6, 188–9
 FTD-ALS, 8, 21, 77, 188
 genetic testing, 161–2
 mutation frequency, 186
 neuroimaging, 134
 neuropathology, 175–6, 189
 pathophysiology, 177, 188–9, 197–8, 199
 primary progressive aphasia, 63
 psychotic symptoms, 35, 73, 96
 repeat length effects, 191
 therapeutic targeting, 251–2
- Caenorhabditis elegans*, 171, 254
- Cambridge Prospective Memory Test, 109
- Cambridge Semantic Memory Battery, 117, 119
- carbamazepine, 247
- caregivers, 230–1. *See also* family as informants, 47–8, 98–9
 burden, 222, 223
 clinician relationships, 230, 265–7
 education, 223, 224, 234
 managing functional disability, 223–4
 support for, 36–7, 237–8, 267–70
- CBD. *See* corticobasal degeneration
- cerebrospinal fluid (CSF) biomarkers, 101, 143–6, 148, 255
- cerebrovascular disease, 24–5, 34
- children
 as carers, 223
 of FTD patients, 236, 266
 safety concerns, 236
- CHMP2B* gene mutations, 7–8, 181, 189–90
 mutation frequency, 186
 pathophysiology and animal models, 205–6
- cholinesterase inhibitors. *See* acetylcholinesterase inhibitors
- chromosome 17-linked disease. *See* frontotemporal dementia with parkinsonism-17
- chromosome 3-linked disease (FTD-3), 7–8, 181
- citalopram, 244
- classification, disease, 15–16
- clinical course, 35–6, 102
- Clinical Dementia Rating Scale (CDR), 213
- Clinical Dementia Rating Scale for Frontotemporal Dementia (CDR-FTD), 213
- clinical presentations, 30–40
 atypical, and differential diagnosis, 33–5
 case studies, 38–40
 classical, 31–3
 imaging correlations, 137–9
 clinical syndromes, 16–21, 93–4
 molecular correlates, 166, 181
 neuroimaging, 125–33
- clinical trials, 255, 267
- clinicopathologic correlations, 23, 93
- clomipramine, 244
- clozapine, 231–2
- cognitive assessment. *See also* neuropsychological testing
 behavioral variant FTD, 49
 FTD-ALS, 73–4
 office-based, 99
- cognitive deficits
 behavioral variant FTD, 31–2, 48–9
 FTD-ALS, 69–70
 imaging correlations, 138
 impact on functional ability, 214, 220–2
 management, 232–4
- communication impairments. *See also* language disturbances
 management, 218, 224, 234–5
- community care, 267
- compulsive behaviors, 46–7, 96–7
 imaging studies, 138
 management, 231, 232, 236
- Conners' Continuous Performance Test (CPT), 107
- constructional abilities, 49
- continuity of care, 231
- “Cookie Theft” picture, Boston Test, 120
- corticobasal degeneration (CBD), 20, 82–7
 biomarkers, 87
 clinical phenotypes, 84–6
 clinicopathologic correlation, 23, 24
 diagnostic criteria, 85–6
 functional disability, 220, 221
 genetics, 84
 imaging, 86–7, 137
 overlap with primary progressive aphasia, 18
 pathology, 22, 83–4, 169–70
 pharmacotherapy, 233

Index

- corticobasal degeneration (*cont.*)
 progressive non-fluent aphasia, 57, 58
 use of term, 20, 85
- corticobasal degeneration syndrome (CBDS), 20, 82–3
- corticobasal syndrome (CBS), 8–9, 85–6
 Alzheimer's disease pathology with, 24
 imaging, 86–7
 PSP pathology with (PSP-CBS), 85
 use of term, 20, 85
- corticodentatonigril degeneration with neuronal achromasia, 82
- Creutzfeldt–Jakob disease (CJD), 25, 94
- davunetide, 250, 254, 255
- day programs, 237
- decision-making deficits, 50–1
- dementia of frontal type, 3, 15
- dementia with Lewy bodies (DLB)
 clinicopathologic correlation, 23
 differential diagnosis, 34
 imaging, 137
 TDP-43 pathology, 176–7
- dementias, rapidly progressive (RPD), 94–5
- demographics, disease, 92
- depression
 differential diagnosis, 34–5, 96
 management, 237
- dextroamphetamine, 246
- diagnosis, 229–30
 family's journey, 262–5
 longitudinal reassessment, 102
 management after, 265–7
 methods, 98–101
 recommended terminology, 102
- dietary preferences, altered. *See* eating behavior
- differential diagnosis, 23–5, 33–5, 94–8
- diffusion tensor imaging (DTI)
 behavioral variant FTD, 127
 FTD-ALS, 74–6, 130
 genetic FTD syndromes, 135
 logopenic progressive aphasia, 133
 progressive non-fluent aphasia, 59, 133
 semantic dementia, 132
- Digit Span Forward test, 107
- dipeptide repeat (DPR) protein
 pathology, 175–6, 188–9
- disability, functional. *See* functional disability
- disease-modifying treatments, potential, 248–54
- disinhibition
 behavioral variant FTD, 16, 31, 45–6
 case study, 38
 imaging studies, 138
 impact on daily life, 217
 management, 218, 231–2, 235–6
- D-KEFS (Delis–Kaplan Executive Function System), 112
- Dominantly Inherited Alzheimer's Network (DIAN), 254
- donepezil, 245
- dopamine augmentation therapies, 233, 246–7, 248
- dressing, 215–16, 219
- driving, 214, 215, 217–18, 219
- Drosophila melanogaster*, 171, 198, 254
- dual-task impairments, 71, 76
- dysexecutive syndrome. *See* executive dysfunction
- dyslexia
 phonologic, 138
 surface, 138
- dystonia, management, 232
- dystrophic neurites (DN), 172, 173
 familial FTLT-DTP, 175, 176
 FET-positive, 178
 FTLT-DTP subtypes, 174, 175
- eating behavior
 behavioral variant FTD, 31, 38, 47, 216
 imaging studies, 138
 management, 216, 219, 232, 236
 semantic dementia, 217
- Edinburgh Cognitive and Behavioural ALS Screen (ECAS), 74, 75
- education
 carer, 223, 224, 234
 healthcare professionals, 270
- electroencephalography (EEG), 100
- electromyography, 101
- Emotional Morphing Test, 114
- emotional processing deficits
 behavioral variant FTD, 50
 FTD-ALS, 72–3
 imaging studies, 139
 testing, 113–14
- empathy, loss of, 31, 46
 imaging studies, 138
 management, 236
- employment, 267
- environmental modifications, 223–4, 235
- epidemiology, 30–1
- epothilone D, 250
- EWS (Ewing's sarcoma) protein, 177, 178, 179, 180
- Executive and Social Cognition Battery (ESCB), 115
- executive dysfunction
 behavioral variant FTD, 5, 16–17, 31, 48–9
 FTD-ALS, 70–1
 imaging studies, 138, 139
 management, 215, 232, 233–4
 testing, 110–12
- extrapyramidal symptoms. *See* parkinsonism/extrapyramidal symptoms
- Face task, 112
- Face-Place Test, 109–10
- falls, 84–5, 231, 232, 235
- familial frontotemporal dementia. *See* also genetics
 FTDP-17. *See* frontotemporal dementia with parkinsonism-17
 imaging, 134–6
 primary progressive aphasia, 62–3
 secondary prevention, 255
 TDP-43 proteinopathies, 175–6
- family, 262–71. *See also* caregivers
 discussing pathology results, 239
 impact of genetic testing, 161, 162
 journey to diagnosis, 262–5
 managing after diagnosis, 265–7
 resources and support, 267–70
- family history, 156
- Faux Pas Test, 112
- FET (FUS/EWS/TAF15) proteins, 177
 arginine hypomethylation, 178, 180
 in disease, 178
 other neurodegenerative diseases, 180
 pathophysiology, 180
 positive FTLT. *See* frontotemporal lobar degeneration with FET pathology
- finances, managing own, 214–15, 218, 219
- financial planning, anticipatory, 266–7
- first- and second-order belief tasks, 112
- [¹⁸F]-fluorodeoxyglucose positron emission tomography (FDG-PET)
 behavioral variant FTD, 129–30
 FTD-ALS, 74
 logopenic progressive aphasia, 61–2, 63
- fluoxetine, 244
- flvoxamine, 244
- Food and Drug Administration (FDA), 243, 255
- food preferences, altered. *See* eating behavior
- footbridge dilemma, 50

- fractional anisotropy (FA)
 behavioral variant FTD, 127
 FTD-ALS, 74–6
 progressive non-fluent aphasia, 133
 semantic dementia, 132
- Free and Cued Selective Reminding Test (FCSRT), 108
- Frontal Assessment Battery (FAB), 99, 110
- Frontal Behavioral Inventory (FBI), 18, 99
- frontal degeneration of non-Alzheimer type, 2–3
- frontal lobe atrophy
 behavioral variant FTD, 6, 125–6, 127, 128
 FTD-ALS, 130, 131
 semantic dementia, 6, 130
- frontal screening tools, 110
- frontal variant frontotemporal dementia. *See* behavioral variant frontotemporal dementia
- frontotemporal dementia-amyotrophic lateral sclerosis (FTD-ALS), 8, 20–1, 68–77
 assessing cognitive and behavioral change, 73–4
 behavior change, 73
 brain imaging, 130, 131
 brain imaging and cognition, 74–6
 case study, 40
 cognitive change, 69–70
 evolution of concept, 68–9
 genetics, 8, 21, 77, 188, 190
 management, 233, 234
 pathology, 22, 76–7, 181
 psychiatric symptoms, 20–1, 73
- Frontotemporal Dementia Behavioural Rating Scale (FTDFRS), 213
- frontotemporal dementia (FTD)
 behavioral variant. *See* behavioral variant frontotemporal dementia
 overlap syndromes, 8–9
 terminology, 5–7, 16, 91, 92
- frontotemporal dementia linked to chromosome 3 (FTD-3), 7–8, 181
- frontotemporal dementia-motor neuron disease (FTD-MND). *See* frontotemporal dementia-amyotrophic lateral sclerosis
- frontotemporal dementia (FTD) spectrum diseases, 16–26
 abbreviations and acronyms, 16
 clinical approach to diagnosis, 91–102
 clinical characteristics, 92–3
 clinical syndromes, 16–21, 93–4
 clinicopathologic correlations, 23, 93
 CSF biomarkers, 143–8
 diagnostic assessment, 98–101
 differential diagnosis, 23–5, 33–5, 94–8
 historical aspects, 1–8, 15
 pathology and molecular genetics, 21–3
 terminology, 2–3, 5–7, 15–16, 91, 92
 uncommon clinical phenotypes, 94
- frontotemporal dementia with parkinsonism-17 (FTDP-17), 7–8
 molecular genetics, 185–6, 187
 pathology, 169, 170
 pharmacologic therapy, 245, 248
- frontotemporal lobar degeneration (FTLD), 5–7, 16, 165
 clinicopathologic relationships, 93
 molecular classification, 166
 use of term, 92
- frontotemporal lobar degeneration with FET pathology (FTLD-FET; FUS proteinopathies), 6, 22, 177–80
 imaging, 137
 pathogenesis, 180, 200–3
 pathologic features, 178, 179
 pathologic subtypes, 166, 178–80
- frontotemporal lobar degeneration with FUS pathology. *See* frontotemporal lobar degeneration with FET pathology
- frontotemporal lobar degeneration with no inclusions (FTLD-ni), 166, 181
- frontotemporal lobar degeneration with tau-positive inclusions (FTLD-T; FTLD-tau; tauopathies), 6, 22, 165–71
 corticobasal degeneration, 83–4, 169
 familial, 7
 FTD and parkinsonism (FTDP-17 *MAPT*), 170
 globular glial tauopathies, 170
 imaging studies, 137
 models and pathophysiology, 171, 199–200, 201
 molecular pathology, 186–7
 pathologic features, 166–7, 168
 pathologic subtypes, 22, 166, 168–9, 171
 Pick's disease, 168
 potential therapies, 248–50
 prognostic value, 102
- progressive supranuclear palsy, 83–4, 168–9
- frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP), 6, 22, 171–6
 familial, 175–6
 FTD-ALS, 76
 imaging studies, 137
 pathogenesis, 177, 200–3
 pathologic features, 172, 173
 pathologic subtypes, 166, 172–4, 176
 potential treatments, 250
 type A, 174–5
 type B, 174, 175
 type C, 174, 175
 type D, 174, 175
- frontotemporal lobar degeneration with ubiquitin-positive pathology (FTLD-U), 22
 atypical, 22, 177, 178, 179
 FTD-ALS, 76
 imaging, 134–5
 subtypes, 22
- frontotemporal lobar degeneration with ubiquitin proteasome system-positive pathology (FTLD-UPS), 166, 180–1
- FTD. *See* frontotemporal dementia
- FTD Treatment Study Group, 269
- FTDP-17. *See* frontotemporal dementia with parkinsonism-17
- FTLD. *See* frontotemporal lobar degeneration
- functional disability, 211
 anatomical correlates, 221–2
 assessment, 212, 213
 behavioral variant FTD, 213–14, 215, 216, 220
 carer burden, 222, 223
 case studies, 225–6
 cognitive and behavioral changes and, 214, 220–2
 corticobasal degeneration, 220, 221
 logopenic progressive aphasia, 219–20
 management, 223–4, 230–1
 patterns and progression, 213
 progressive non-fluent aphasia, 217–18, 219, 220
 progressive supranuclear palsy, 220, 221
 semantic dementia, 216–17, 218, 219, 220
- functional magnetic resonance imaging (fMRI; rsfMRI)
 behavioral variant FTD, 127–8, 129
 FTD-ALS, 74
 genetic FTD syndromes, 135–6

Index

- FUS (fused in sarcoma) protein, 177, 178, 200–3
 FTD-ALS, 76
 pathophysiology, 180, 202, 203–4
 positive inclusions, 178, 179
 FUS gene mutations, 180, 186, 190
 FUS proteinopathies. *See* frontotemporal lobar degeneration with FET pathology
- galantamine, 37, 245
 genetic counseling, 153–63
 Genetic Frontotemporal dementia Initiative (GENFI), 255
 Genetic Information Non-discrimination Act (GINA), 158
 genetic testing, 154, 155, 157–9
 impact on families, 161, 162
 interpreting results, 161–2
 predictive, 157–9, 161, 162–3
 genetics, 22–3, 185–6, 192
 Mendelian genes, 185–90
 pathologic correlations, 21
 primary progressive aphasia, 62–3
 susceptibility genes and risk loci, 190–1
 genome-wide association studies (GWAS), 190, 191
 glial cytoplasmic inclusions (GCI), 172, 173, 174–5
 globular glial inclusions (GGI), 169, 170
 globular glial tauopathies (GGT), 169, 170
 glycogen synthase kinase 3 (GSK3), 147, 249
 Gogi aphasia, 4
 G-quadruplex structures, 197–8
 Graded Faces Test (GFT), 109
 grains, argyrophilic, 169, 171
 granulin peptides (GRN), 144, 187, 201
 GRN gene mutations, 187–8, 200–3
 animal models, 203, 253–4
 case history, 154–5
 clinical presentation, 94, 187–8
 CSF progranulin levels, 144
 discovery, 7
 mutation frequency, 186
 neuroimaging, 133, 134–6
 neuropathology, 175, 187
 pathophysiology, 177, 201–3
 primary progressive aphasia, 62–3
 serum progranulin levels, 144
 GRN gene variants, 191
- Hayling and Brixton test, 111–12
 healthcare professionals, education, 270
- hereditary diffuse leukoencephalopathy with spheroids, 181
 historical perspectives, 1–8, 15
 history taking, clinical, 98–9
 hoarding disorder, 97
 Holiday Apartment Task, 71
 hospice care, 239
 Hotel Task, 114
 household chores, 215, 217, 218, 219
 hummingbird sign, 86
 Huntington's disease, 95, 180
 hygiene, personal, 215–16, 217, 219
 hyperorality, 17, 47. *See also* eating behavior
 hyperthyroidism, 99
- imaging, 125–39
 clinical correlations, 137–9
 clinical syndromes, 125–33
 clinical trials, 255
 comparative studies, 133
 diagnostic evaluation, 100–1
 functional disability and, 221–2
 genetic syndromes, 134–6
 other neurodegenerative disorders, 137
 pathologic syndromes, 137
 immunotherapies, 249–50
 impulsive behavior, management, 232, 235–6
 inclusion body myopathy, Paget's disease of bone and frontotemporal dementia (IBMPFD), 176, 189, 205
 incontinence, 216, 219
 induced pluripotent stem cells (iPS), 253, 269
 Ineco Frontal Screening (IFS), 110
 inertia. *See* apathy/inertia
 inflammation, 201–3, 251
 insular atrophy, 125–6, 130
 International Behavioral Variant Frontotemporal Dementia Criteria Consortium (FTDC), 45
 international support groups, 270
 α -internexin, 178–9, 180
 Interpersonal Reactivity Index (IRI), 114
 intranuclear inclusion body disease, 180
 Iowa Gambling Task (IGT), 50, 71, 114–15
- Kissing and Dancing Test (KDT), 117
 Klüver–Bucy syndrome, similarities to, 17, 47
- language disturbances, 18. *See also* aphasia
 FTD-ALS, 71–2
 imaging correlates, 138
 management, 232, 234–5
 progressive non-fluent aphasia, 32–3
 testing, 56, 115–16
 legal planning, anticipatory, 266–7
 leisure activities, 217, 218, 235
 letter fluency deficits. *See* phonemic fluency deficits
 Letters and Numbers Test, 110
 levodopa, 233, 248
 lipid-storage disorders, 95
 lithium, 233, 249
 LMTx (methylene blue), 249
 logopenic progressive aphasia (LPA; lvPPA), 20, 61–2, 92
 behavioral variant FTD vs., 133
 clinical presentation, 33
 core differential features, 61
 differential diagnosis, 62
 functional disability, 219–20
 genetics, 62–3
 historical aspects, 4
 imaging, 61–2, 133, 135
 imaging–clinical correlations, 138–9
 neuropsychological testing, 117–20
 pathology, 61–2, 63
- magnetic resonance imaging (MRI), 125
 behavioral variant FTD, 125–6, 128
 clinical trials, 255
 diagnostic assessment, 100, 101
 FTD-ALS, 74–6, 130, 131
 functional. *See* functional magnetic resonance imaging
 genetic FTD syndromes, 134–6
 logopenic progressive aphasia, 61, 62, 133, 135
 progressive non-fluent aphasia, 101, 132–3, 134
 semantic dementia, 130–2
 management, 36–7, 229–38, 239
 advanced stages, 238–9
 functional disability, 223–4
 initial/early stage, 229–30, 265–7
 middle stage, 230–8
 non-pharmacologic, 233–8
 pharmacologic. *See* pharmacologic therapy
 mania, differential diagnosis, 96
 MAPT gene, 166, 167
 variants, 191
 MAPT (tau) mutations, 167, 168, 185–7
 case history, 160–1
 clinical presentation, 187

- corticobasal degeneration, 84
 historical aspects, 2, 7
 mouse models, 253
 mutation frequency, 186
 neuroimaging, 134, 135–6
 neuropathology, 169, 170, 186–7
 pathophysiology, 199–200
 primary progressive aphasia, 62
 progressive supranuclear palsy, 84
 meal preparation, 215, 217, 218, 219
 Medication Scheduling Task, 71
 medications, managing own, 215, 217
 memantine, 37, 233, 247–8
 memory function
 behavioral variant FTD, 49, 107–8
 imaging studies, 138
 semantic dementia, 19
 testing, 107–9
 Mendelian genes, 185–90
 methylene blue, 249
 methylphenidate, 233, 246–7
 microtubule-associated tau protein
 (MAPT). *See* tau
 microtubule-stabilizing agents, 250
 Mind in the Eyes Test, 112
 Mind in the Voice Test, 112
 Mini-Mental State Examination
 (MMSE), 17–18, 99, 106
 mitochondrial disorders, 95
 molecular pathology subtypes, 21,
 22–3, 166
 monoclonal antibodies, anti-tau,
 249–50
 Montreal Cognitive Assessment
 (MOCA), 99
 motor neuron disease (MND). *See*
 amyotrophic lateral sclerosis
 motor neuron disease inclusion
 dementia (MNDID), 21
 motor neuron disease type inclusions
 (MNDI), 22
 motor symptoms. *See also*
 parkinsonism/
 extrapyramidal symptoms
 management, 232, 233, 235
 mouse models, 253–4. *See also*
 transgenic mouse models
 MRI. *See* magnetic resonance imaging
 multidisciplinary management, 238
 Multiple Errands Test Hospital Version
 (MET-HV), 114
 multiple system tauopathy with
 dementia, sporadic, 170
 mutism, 18–19, 21, 72
 imaging studies, 138
 naming deficits. *See* anomia/naming
 deficits
 naming tests, 118
 Nasu–Hakola disease, 181
 National Alzheimer's Coordinating
 Center (NACC), 269
 National Alzheimer's Project Act
 (NAPA), 270
 neurodegenerative diseases, other
 differential diagnosis, 33–4
 FET proteins, 180
 imaging studies, 137
 overlap with, 30
 rare frontal variants, 181
 TDP-43 pathology, 176–7
 neurofibrillary tangle
 (NFT)-dementia, 169, 171
 neurofibrillary tangles (NFT), 84
 progressive supranuclear palsy,
 168
 transgenic mouse models, 200, 201
 neurofilaments
 CSF, 146, 147, 255
 immunoreactive inclusions, 178–9,
 180
 neuroimaging. *See* imaging
 neurologic disorders, differential
 diagnosis, 94–5
 neurologic examination, 100
 neurologic signs, behavioral variant
 FTD, 32
 neuronal cytoplasmic inclusions
 (NCI), 172, 173
 dipeptide repeat (DPR)
 protein-positive, 176
 familial FTLT-TDP, 175, 176
 FTLD-FET, 178, 179–80
 FTLD-TDP subtypes, 174, 175
 neuronal intermediate filament
 inclusion disease (NIFID), 22,
 177, 178–9, 180
 neuronal intermediate filaments. *See*
 neurofilaments
 neuronal intranuclear inclusions (NII),
 172, 173
 dipeptide repeat (DPR)
 protein-positive, 176
 familial FTLT-TDP, 175, 176
 FTLD-FET subtypes, 178, 179–80
 FTLD-TDP subtypes, 174, 175
 other neurodegenerative diseases,
 180
 neurons, swollen achromatic, 22, 170
 neuropathology, 6–7, 21–2, 165–82
 discussion with family, 239
 imaging studies, 137
 molecular classification, 166, 181
 Neuropsychiatric Inventory (NPI), 99,
 255
 neuropsychological testing, 100,
 106–20. *See also* cognitive
 assessment
 behavioral variant FTD, 106–16
 primary progressive aphasia, 56–7,
 117–20
 nihilism, avoiding, 266
 nimodipine, 251
 NMDA receptor antagonists. *See*
 memantine
 non-fluent variant primary progressive
 aphasia. *See* progressive
 non-fluent aphasia
 non-pharmacologic interventions,
 233–8
 normal pressure hydrocephalus
 (NPH), 95
 Northwestern Anagram Test, 56
 obsessive–compulsive disorder
 (OCD), 96–7
 olanzapine, 231, 246
 OPTN gene mutations, 69, 77
 oral speech production test, 120
 oxytocin, 37, 233
 paclitaxel, 250
 Paired Associate Learning Test (PAL),
 computerized, 108
 palliative care, 239
 parkinsonism/extrapyramidal
 symptoms
 chromosome 17-linked. *See*
 frontotemporal dementia with
 parkinsonism-17
 corticobasal degeneration, 20
 FTD with, 82, 83
 management, 232, 248
 progressive supranuclear palsy with
 (PSP-P), 85
 paroxetine, 37, 244
 pathology. *See* neuropathology
 pathophysiology, 197–206
 pedigrees
 eliciting, 156
 example, 155, 158, 160
 penguin sign, 86
 perseverative behaviors, 46–7, 85
 management, 232, 236
 PET. *See* positron emission
 tomography
 pharmaceutical industry, 254
 pharmacologic therapy, 243–56
 disease-modifying treatments,
 248–54
 future directions, 254–5
 models for drug development,
 252–4
 symptomatic treatment, 37, 231–2,
 233, 243–8
 phenocopy cases, behavioral variant
 FTD, 3, 25, 35, 94, 130

Index

- phonemic (or letter) fluency deficits
 behavioral variant FTD, 48
 FTD-ALS, 70–1
 logopenic progressive aphasia, 61
 phonologic errors, 61
 phosphorylated tau (P-tau), 145, 167, 199
 as therapeutic target, 248, 249
 CSF levels, 145, 146
 Pick, Arnold, 1–2, 15
 Pick bodies, 2, 6, 22, 168, 169
 Pick cells, 2, 22, 168
 Pick complex, 6, 16. *See also*
 frontotemporal dementia (FTD)
 spectrum diseases
 Pick type A pathology, 22
 Pick type B pathology, 22. *See also*
 corticobasal degeneration
 Pick type C pathology, 22
 Pick's disease (PiD), 1–2, 15, 82
 imaging, 137
 pathology, 168, 169
 use of term, 16
 pigmented orthochromatic
 leukodystrophy, 181
 Pittsburgh compound B (PiB) positron
 emission tomography (PET)
 behavioral variant FTD, 130
 logopenic progressive aphasia, 4,
 61–2, 133
 progressive non-fluent aphasia, 101
 pluripotent stem cells, induced (iPS),
 253, 269
 poly-(glycine-proline) peptides, 252
 positron emission tomography (PET),
 100–1, 125, 255
 behavioral variant FTD, 128–30
 logopenic progressive aphasia, 61–2,
 63
 progressive non-fluent aphasia, 101
 predictive genetic testing, 157–9, 161,
 162–3
 presenilin 1 (*PSEN1*) gene mutations,
 24, 33
 primary lateral sclerosis (PLS), 69
 primary progressive aphasia (PPA),
 3–5, 55–64
 atypical/mixed cases, 62
 behavioral variant FTD vs., 133
 classification, 5–6
 clinical syndromes, 18–19
 clinicopathologic correlation, 19, 23
 diagnosis, 55, 229
 differential diagnosis, 24, 33–4
 genetic studies, 62–3
 imaging, 130–3
 imaging–clinical correlations, 138–9
 logopenic/phonologic variant. *See*
 logopenic progressive aphasia
 management, 63–4, 230, 234–5
 neuropsychological testing, 56–7,
 117–20
 non-fluent/agrammatic variant. *See*
 progressive non-fluent aphasia
 prognosis, 102
 semantic variant. *See* semantic
 dementia
 use of term, 91, 92
 variants, 57–61, 62
 prion diseases, 25, 34, 94
 prognosis, disease, 102
 progranulin (PGRN), 144, 187,
 201–3
 CSF levels, 144, 146
 gene mutations. *See* *GRN* gene
 mutations
 serum levels, 144
 therapeutic targeting, 250–1
 progression, disease, 35–6, 102, 213
 Progressive Aphasia Severity Scale
 (PASS), 230
 progressive muscular atrophy (PMA),
 69
 progressive non-fluent aphasia (PNFA;
nfvPPA), 57–9, 92
 behavioral variant FTD vs., 133
 classification, 5, 6
 clinical presentation, 32–3, 57
 clinical syndrome, 18–19
 core differential features, 61
 differential diagnosis, 33–4
 functional disability, 217–18, 219,
 220
 genetics, 62–3
 historical aspects, 4
 imaging, 101, 132–3, 134
 imaging–clinical correlations,
 138–9
 neuropsychological testing, 117–20
 pathology, 7, 23, 57–8, 59, 181
 PSP variant (PSP-PNFA), 85
 progressive supranuclear palsy (PSP),
 20, 82–7
 biomarkers, 87
 clinical phenotypes, 84–5
 clinicopathologic correlation, 23, 24
 corticobasal syndrome with
 (PSP-CBS), 85
 functional disability, 220, 221
 genetics, 84
 imaging, 86–7
 parkinsonism with (PSP-P), 85
 pathology, 83–4, 168–9
 pharmacotherapy, 233
 progressive non-fluent aphasia
 variant (PSP-PNFA), 85
 pure akinesia with gait freezing
 (PSP-PAGF), 85
 Richardson's syndrome (PSP-RS),
 85, 168
 prosopagnosia, 5, 20, 32
 imaging studies, 139
 protein kinase inhibitors, 249
 proteomic studies, 147–8
 PSP. *See* progressive supranuclear
 palsy
 psychiatric disorders
 differential diagnosis, 34–5, 95–8
 misdiagnosis, 229
 psychiatric history, prior, 98–9
 Psycholinguistic Assessment of
 Language Processing in Aphasia
 (PALPA), 118, 119–20
 psychotic/psychiatric symptoms
 atypical presentations with, 94
 behavioral variant FTD, 31
C9orf72 mutations, 35, 73, 96
 case study, 40
 FTD-ALS, 20–1, 73
 management, 231–2, 235–7
 pure progressive aphemia, 18
 Pyramids and Palm Trees (PPT) Test,
 117
 quetiapine, 231, 246
 rapidly progressive dementias (RPD),
 94–5
 reading deficits, 32, 59
 reading studies, 138
 reading tests, 56, 119–20
 relatives. *See* family
 Repeat and Point Test, 117
 repeat-associated non-ATG (RAN)
 translation, 199, 252
 repetition tests, 56, 120
 research, 267, 269
 residential care, 238–9, 267
 retirement, early, 267
 Rey–Osterrieth complex figure test,
 109
 Richardson's syndrome (PSP-RS), 85,
 168
 rigid time-constrained routines, 217,
 218, 225
 riluzole, 233
 risperidone, 232, 246
 rivastigmine, 245
 sagging brain syndrome, 95
 schizophrenia. *See also* psychotic/
 psychiatric symptoms
 ALS association, 73
 differential diagnosis, 34–5, 97–8
 secondary prevention, familial FTD,
 255
 seizure disorders, 95

- selective serotonin reuptake inhibitors (SSRIs), 37, 231, 244
- selegiline, 246
- semantic dementia (SD; svPPA), 59–61, 92
- behavioral variant FTD vs., 133
 - case studies, 39–40, 225
 - classification, 5, 6
 - clinical presentation, 32, 59
 - clinical syndrome, 19–20
 - core differential features, 61
 - differential diagnosis, 33–4
 - functional disability, 216–17, 218, 219, 220
 - genetics, 62–3, 191–2
 - historical aspects, 4–5
 - imaging, 59, 60, 130–2
 - imaging–clinical correlations, 138–9
 - left temporal predominant, 5, 19, 39–40, 130–1
 - neuropsychological testing, 117–20
 - pathology, 7, 23, 181
 - prognosis, 102
 - right temporal predominant, 5, 39, 131
- semantic fluency test, 118
- semantic memory, 4
- tests, 117–18
- sentence–picture matching tasks, 56, 118
- septin 11 (SEPT11), 148
- sertraline, 244
- sex distribution, 92
- shopping, 214, 215, 217, 218
- single-photon emission computed tomography (SPECT), 125, 128–30
- social activities, 217, 218, 235
- social cognition
- behavioral variant FTD, 50
 - FTD-ALS, 72–3
 - imaging studies, 138
 - testing, 112–14
- Social cognition and Emotional Assessment (SEA), 100, 115
- Social Observer Behavior Checklist, 48
- social relationships, disrupted, 266
- SOD1* gene mutations, 69, 77
- sortilin (SORT1), 251
- SPECT. *See* single-photon emission computed tomography
- speech disturbances
- FTD-ALS, 21, 71
 - imaging studies, 138
 - primary progressive aphasia, 18
 - progressive non-fluent aphasia, 32–3, 57
- speech-language pathologists (SLPs), 234–5
- spinocerebellar ataxia, 180
- Steele–Richardson–Olszewski syndrome. *See* progressive supranuclear palsy
- stereotyped behaviors, 46–7, 236
- stress granules, 203–4
- Stroop Color and Word Test, 107
- subcortical involvement
- behavioral variant FTD, 125, 126
 - corticobasal degeneration, 83, 170
 - FTLD with TDP-43 pathology, 172, 174
 - progressive supranuclear palsy, 83, 168
 - semantic dementia, 130
- suberoylanilide hydroxamic acid (SAHA), 251
- supranuclear gaze palsy, 85
- survival rates, 36, 102
- susceptibility genes, 190–1
- symptomatic pharmacologic treatment, 37, 231–2, 233, 243–8
- synonym judgments task, 118
- TAF15 protein, 177, 178, 179, 180
- TARDBP* mutations, 176, 190
- animal models, 204–5
 - mutation frequency, 186
- tau, 83–4, 145, 199–200
- CSF levels, 87, 145, 146
 - disease-specific markers, 87
 - isoforms, 83–4, 166, 167
 - monoclonal antibodies, 249–50
 - normal expression and function, 165–6
 - pathologic forms, 166–7, 168
 - pathophysiology, 171, 199–200, 201
 - phosphorylated. *See* phosphorylated tau
 - therapeutic targeting, 248–50
 - vaccines, 249
- tau 33 kDa/55 kDa ratio, CSF, 87
- tau gene. *See* *MAPT* gene
- tau positron emission tomography (PET), 100–1, 255
- tau-positive inclusions, 6
- corticobasal degeneration, 170
 - FTDP-17, 7
 - FTLD with. *See* frontotemporal lobar degeneration with tau-positive inclusions
 - globular glial inclusions, 170
 - MAPT* mutations, 170
 - Pick's disease. *See* Pick bodies
 - progressive supranuclear palsy, 168
- tauopathies. *See* frontotemporal lobar degeneration with tau-positive inclusions
- taxanes, 250
- TDP-43, 144, 172, 200–3
- CSF levels, 144, 146
 - gene mutations. *See* *TARDBP* mutations
 - in disease, 172
 - mouse models, 253–4
 - pathologic forms, 172, 174
 - pathophysiology, 177, 202, 203–4
 - plasma levels, 144
 - therapeutic targeting, 250
- TDP-43 pathology, 6, 172, 173
- FTLD with. *See* frontotemporal lobar degeneration with TDP-43 pathology
 - other neurodegenerative diseases, 176–7
- telephone use, 215, 218, 219
- temporal lobe atrophy
- behavioral variant FTD, 125–6, 128
 - FTD-ALS, 130, 131
 - Pick's original cases, 1–2
 - semantic dementia, 5, 19, 59, 130–2
- temporal lobe seizure disorders, 95
- terminology
- diagnostic, 102
 - disease, 2–3, 15–16, 91, 92
- theory of mind (ToM) deficits
- behavioral variant FTD, 50
 - FTD-ALS, 72
 - testing, 112–13
- Theory of mind cartoons, 113
- Theory of mind stories, 113
- tideglusib, 249
- TMEM106B* gene, 190
- tolcapone, 233
- topiramate, 247
- Tower of London Test, 111
- TPI-287, 250
- Trail Making Test, 107, 111
- transactive response DNA-binding protein 43. *See* TDP-43
- transcortical sensory aphasia, 4, 19
- transgenic mouse models, 171, 200, 205, 253–4
- transmissible spongiform encephalopathies. *See* prion diseases
- transportin 1 (Trn1), 177, 179, 180
- trazodone, 37, 231, 244
- treatment, 37
- pharmacologic. *See* pharmacologic therapy
 - symptomatic, 232
- tumor necrosis factor- α (TNF- α), 201–3, 251

Index

- ubiquitin-positive pathology. *See*
 frontotemporal lobar
 degeneration with ubiquitin-
 positive pathology
 utilization behavior, 17
- valproic acid, 247
- vascular dementia (VaD), 24–5, 34
- VCP mutations, 189, 205
 animal models, 205
 mutation frequency, 186
 neuropathology, 176, 189
- pathophysiology, 177, 189, 205
- verbal fluency deficits
 behavioral variant FTD, 48
 FTD-ALS, 70–1
 logopenic progressive aphasia, 61
 progressive non-fluent aphasia, 57
 testing, 110–11
- verbal fluency index (*Vfi*), 70, 71
- Visual Object and Space Perception
 Test (VOSP), 109
- visuospatial function, 49
 testing, 109–10
- Western Aphasia Battery, 56
- white matter degenerative diseases,
 95
- Wilson's disease, 95
- Wisconsin Card Sorting Test,
 111
- word fluency tests, 110–11
- Word Picture Matching task, 118
- Words and Sentences Repetition test,
 120
- zebra fish, 199, 254